Each cell in your body relies on precise communication with other cells to function properly. At the center of this process ...

Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...

Abalone Bio, an antibody company measuring large-scale activity data to drive AI-powered discovery of active therapeutics, ...

A recent study published in Engineering delves into the complex mechanisms of drug addiction, highlighting the crucial role of astrocytic G protein-coupled receptors (GPCRs).

The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.

G protein-coupled receptors (GPCRs) are integral membrane proteins with seven membrane-spanning helices. Upon binding to a ligand – which can range from small molecules like cyclic AMP to ...

A new review highlights how gut microbiome imbalances contribute to cardiovascular disease by altering short-chain fatty ...

Researchers at Monash University have uncovered how the gut—and the food we eat—affects high blood pressure. Their discovery ...

Cambridge, UK-based biotech start-up Maxion Therapeutics, which is developing antibody-based KnotBody drugs for ion channel- ...

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...

NIH-Funded Research Team Engineers New Drug Targeting Pain Sensation Pathway with Implications for Chronic Pain Treatment ...

Endocannabinoids are lipid mediators that interact with G protein-coupled receptors, including cannabinoid CB2 receptor (CB2R), which is mainly expressed in peripheral tissues with immune functions.